Ticker brief

ZURA

last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
21
authors 14d
11
crowd 14d
-0.9σ

No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.

Sentiment — last 14 days
daily mean sentiment, 2026-10-05 → 2026-10-16 · now -0.10 (−1 bearish … +1 bullish)
Who spoke11
authorgradetrader scoresignalsmean sent
@semodoughC-1.064+0.21
@PrismMarketViewC·3+0.25
@PrismDMA-2.762+0.18
@Maximus_HollaC-2.132+0.35
@OptionsFlowBossC·2+0.30
@bioinvestor24A-0.872+0.58
@SandmanMarketsC+0.582+0.55
@BiopharmIQB·1+0.00
@FlowbyBobbyC·1+0.40
@zohmbasticC-2.941+0.10
@LogicalThesisA-1.211-0.25
Recent signals21of 21 in 14d — receipts included
date (PT)authorsentwhat they saidsince thenreceipt
2026-10-16@LogicalThesis-0.25Says ZURA's decline reflects broad biotechnology weakness rather than company-specific news.·
2026-10-16@semodough+0.05A 61-page Schimmer deep dive on ZURA is noted without its conclusions.·
2026-10-15@semodough+0.00Cantor schedules a ZURA fireside chat for October 22 at 10 a.m. ET.·
2026-10-15@SandmanMarkets+0.45ZURA's chart looks constructive, with large prior-day volume and OBV near resistance.·
2026-10-15@SandmanMarkets+0.65Buy ITW, WINA and ZURA; watch CI, CME and HCSG for confirmation. — Explicit buy list names three stocks and separately identifies three valid watch setups.·
2026-10-14@semodough+0.40Reports Oppenheimer's $16 ZURA target and expectations for a December TibuSHIELD readout.·
2026-10-14@OptionsFlowBoss+0.00Reports open-interest changes with direction visible only in the chart.·
2026-10-13@zohmbastic+0.10Lists the largest ZURA call trade, volume strike, and open-interest strike by expiry.·
2026-10-13@bioinvestor24+0.55Argues TL1A antibodies such as ZURA's are safer and will outlast IL-17 approaches.·
2026-10-13@bioinvestor24+0.60Predicts TL1A agents including ZURA's will displace more toxic IL-17 therapies.·
2026-10-13@FlowbyBobby+0.40Whale flow shows $220K in ZURA $7.50 calls expiring December 18, 2026.·
2026-10-13@OptionsFlowBoss+0.60Lists unusual bullish options-volume multiples; capped at six tickers.·
2026-10-13@Maximus_Holla+0.25Author reacts positively after understanding ZURA's volatility catalyst.·
2026-10-13@Maximus_Holla+0.45Enthusiastic language expresses a positive stance on ZURA.·
2026-10-09@BiopharmIQ+0.00Summarizes large biotech moves tied to a buyout and trial outcomes, then flags upcoming studies.·
2026-10-07@PrismDM+0.20Reports ZURA up 9% and identifies a 247-patient Phase 2 readout due this quarter.·
2026-10-07@PrismMarketView+0.25Notes Zura's 247-patient Phase 2 readout is due this quarter.·
2026-10-07@PrismMarketView+0.30Reports intraday percentage moves and volume for several small-cap stocks.·
2026-10-07@PrismDM+0.15Lists intraday percentage moves, prices, and PBK volume across five healthcare and energy names.·
2026-10-05@PrismMarketView+0.20Reports Zura's addition to a publisher index and dates for upcoming Phase 2 catalysts.·
2026-10-05@semodough+0.40Leerink reiterates Outperform based on underappreciated value and tibulizumab's multi-indication potential.·

“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.